Literature DB >> 10023648

Timely initiation of dialysis: a urea kinetic approach.

P R Keshaviah1, P F Emerson, K D Nolph.   

Abstract

The traditional approach of initiating dialysis when the patient begins to manifest uremic symptoms may result in the development of significant malnutrition with detrimental effects on subsequent morbidity and mortality. The recently issued Dialysis Outcome Quality Initiative guidelines suggest that dialysis be initiated when the Kt/V from residual renal function decreases to less than 2.0. We have used the urea kinetic model to show how dialytic dose can be titrated to compensate for declining renal function while maintaining a constant total dose of delivered therapy (Kt/V = 2.0). For hemodialysis (HD), we show that initiating dialysis with once-weekly therapy may be a viable option only for a few months, being replaced by twice-weekly and subsequently with the more typical regimen of thrice-weekly HD. We recommend that the patient be directly initiated with twice-weekly HD to minimize wide swings in the serum concentrations of small-molecular-weight solutes. With continuous ambulatory peritoneal dialysis (CAPD), a hypothetical average-sized patient with high-average transport can be maintained for approximately 8 months with a single 2.5-L nocturnal exchange and from 8 to 17 months with two nocturnal exchanges of 2.5 L each. The use of nocturnal exchanges allows more normal daytime activities and is less intrusive on patient lifestyle. We have shown that both HD and CAPD regimens can be successfully adjusted to achieve a constant total Kt/V of 2.0 for 5 or more years, although CAPD may provide a smoother transition from no dialysis to a complete 10-L regimen.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10023648     DOI: 10.1016/s0272-6386(99)70310-0

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  7 in total

Review 1.  Infrequent dialysis: a new paradigm for hemodialysis initiation.

Authors:  Connie M Rhee; Mark Unruh; Jing Chen; Csaba P Kovesdy; Phillip Zager; Kamyar Kalantar-Zadeh
Journal:  Semin Dial       Date:  2013-09-09       Impact factor: 3.455

Review 2.  Incremental and infrequent hemodialysis: a new paradigm for both dialysis initiation and conservative management.

Authors:  Connie M Rhee; Mehrdad Ghahremani-Ghajar; Yoshitsugu Obi; Kamyar Kalantar-Zadeh
Journal:  Panminerva Med       Date:  2017-01-13       Impact factor: 5.197

3.  Intermittent peritoneal dialysis: urea kinetic modeling and implications of residual kidney function.

Authors:  Steven Guest; Alp Akonur; Arshia Ghaffari; James Sloand; John K Leypoldt
Journal:  Perit Dial Int       Date:  2011-12-01       Impact factor: 1.756

4.  Incremental Hemodialysis: The University of California Irvine Experience.

Authors:  Mehrdad Ghahremani-Ghajar; Vanessa Rojas-Bautista; Wei-Ling Lau; Madeleine Pahl; Miguel Hernandez; Anna Jin; Uttam Reddy; Jason Chou; Yoshitsugu Obi; Kamyar Kalantar-Zadeh; Connie M Rhee
Journal:  Semin Dial       Date:  2017-03-14       Impact factor: 3.455

5.  Incremental Hemodialysis, Residual Kidney Function, and Mortality Risk in Incident Dialysis Patients: A Cohort Study.

Authors:  Yoshitsugu Obi; Elani Streja; Connie M Rhee; Vanessa Ravel; Alpesh N Amin; Adamasco Cupisti; Jing Chen; Anna T Mathew; Csaba P Kovesdy; Rajnish Mehrotra; Kamyar Kalantar-Zadeh
Journal:  Am J Kidney Dis       Date:  2016-02-09       Impact factor: 8.860

6.  Does body fat mass define survival in patients starting peritoneal dialysis?

Authors:  Soo Jeong Choi; Eun Jung Kim; Moo Yong Park; Jin Kuk Kim; Seung Duk Hwang
Journal:  Perit Dial Int       Date:  2013-02-01       Impact factor: 1.756

7.  Protection of Residual Renal Function and Nutritional Treatment: First Step Strategy for Reduction of Uremic Toxins in End-Stage Kidney Disease Patients.

Authors:  Adamasco Cupisti; Piergiorgio Bolasco; Claudia D'Alessandro; Domenico Giannese; Alice Sabatino; Enrico Fiaccadori
Journal:  Toxins (Basel)       Date:  2021-04-19       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.